1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. JNK

JNK

c-Jun N-terminal kinase

JNK (c-Jun N-terminal kinase), a kinase subfamily belonging to the MAPK, is activated in response to various stress stimuli and possesses a wide variety of regulatory functions. The JNK family of serine/threonine protein kinases comprises three isoforms (JNK1, JNK2 and JNK3). JNKs are involved in the emergence and progression of diverse pathologies such as neurodegenerative, cardiovascular and metabolic disorders as well as inflammation and cancer.

Similar to the other MAP kinases, JNKs are activated by a phosphorylation cascade generally involving two types of upstream kinases, the so-called MAP kinase kinase kinases (MAP3K, MKKK) and the MAP kinase kinases (MAP2K; MKK). At the MAP2K level, JNKs are activated by MKK4 and MKK7, the former is a common activator of the JNK and the p38 MAP kinase signaling pathway. The JNK cascade shares various intersection points with other pathways making it a part of a complex signaling network.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-106159
    SB-T-101141
    SB-T-101141 is a novel taxane. SB-T-101141 effectively induces a noncanonical ferroptosis to overcome Paclitaxel (HY-B0015) resistance of breast cancer. SB-T-101141 facilitates the production of iron and ferrous ions and ROS. SB-T-101141 stably binds to KHSRP to inhibit the iron-dependent expression of CISD1 related to iron homeostasis. SB-T-101141 synergistically enhances the iron-dependent activation of JNK and PERK pathways via KHSRP. SB-T-101141 suppresses breast tumor growth in MCF-7(PR)/MDA-MB-231(PR) or KHSRP knock-down MCF-7 xenograft mice model.
    SB-T-101141
  • HY-N0044R
    Ginsenoside Re (Standard)
    Inhibitor
    Ginsenoside Re (Standard) is the analytical standard of Ginsenoside Re. This product is intended for research and analytical applications. Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.
    Ginsenoside Re (Standard)
  • HY-168125
    JNK-IN-18
    Inhibitor
    JNK-IN-18 (compund 23b) is a JNK1 inhibitor with IC50 of 2 nM, compared to JNK2 and BRAF(V600E) with IC50 of 125 nM and 98 nM, respectively.
    JNK-IN-18
  • HY-105178A
    Galarubicin hydrochloride
    Galarubicin hydrochloride (DA 125) is a novel Anthracycline derivative. Galarubicin hydrochloride shows high-affinity DNA binding and topoisomerase II inhibitory activities. Galarubicin hydrochloride induces Apoptosis. Galarubicin hydrochloride exerts cytotoxicity via JNK pathway. Galarubicin hydrochloride can be used in the research of hepatocellular carcinoma.
    Galarubicin hydrochloride
  • HY-151431
    Nrf2/HO-1 activator 2
    Inducer
    Nrf2/HO-1 activator 2 (compound 13m), difluoro-substituted derivative, is a potent Nrf2/HO-1 activator. Nrf2/HO-1 activator 2 has neuroprotective and antioxidant effects through the Nrf2/HO-1 pathway mediated by phosphorylation of ERK1/2, JNK, or Akt in PC12 cells. Nrf2/HO-1 activator 2 can be used in the research of Parkinson's disease (PD).
    Nrf2/HO-1 activator 2
  • HY-174211
    JNK-IN-23
    Inhibitor
    JNK-IN-23 (Compound K12) is an inhibitor of JNK. JNK-IN-23 inhibits the proliferation of MDA-MB-231 (GIC50: 30 nM). JNK-IN-23 blocks TNBC metastatic growth in vivo. JNK-IN-23 inhibits the growth of lung metastases by dual targeting of glutaminase-1 (GLS) and pyruvate dehydrogenase complex (PDHC).
    JNK-IN-23
  • HY-N0809R
    Sesamolin (Standard)
    Inhibitor
    Sesamolin (Standard) is the analytical standard of Sesamolin. This product is intended for research and analytical applications. Sesamolin, isolated from Sesamum indicum, has antioxidative activity, Sesaminol inhibits lipid peroxidation and shows neuroprotection effect. Sesamolin potently inhibits MAPK cascades by preventing phosphorylation of JNK, p38 MAPKs, and caspase-3 but not ERK-MAPK expression.
    Sesamolin (Standard)
  • HY-N3487
    Isodorsmanin A
    Isodorsmanin A is an anti-inflammatory agent. Isodorsmanin A suppresses the production of inflammatory mediators and proinflammatory cytokines. Isodorsmanin A inhibits the phosphorylation of JNK, MAPK.
    Isodorsmanin A
  • HY-P10141
    JNK-IN-15, Cell-Permeable, Negative Control
    Inhibitor
    JNK-IN-15, Cell-Permeable, Negative Control is a negative control of JNK-IN-15, Cell-Permeable (HY-P10140). JNK-IN-15, Cell-Permeable is an inhibitor of JNK.
    JNK-IN-15, Cell-Permeable, Negative Control
  • HY-P11250
    HVF18-a3-d
    Inhibitor
    HVF18-a3-d is an antimicrobial peptide. HVF18-a3-d reduces NO production. HVF18-a3-d inhibits the production of TNF-α and IL-6, reduces ROS production, and suppresses the TLR4 signaling pathway, as well as LPS-induced phosphorylation of ERK, JNK, and p38 MAPK. HVF18-a3-d exhibits antimicrobial activity against a variety of bacteria by disrupting their outer and inner membranes. HVF18-a3-d protects mice from fatal septic shock induced by Acinetobacter baumannii resistant to Carbapenem. HVF18-a3-d shows anti-inflammatory and antioxidant effects.
    HVF18-a3-d
  • HY-P10048
    TAT-JIP
    Inhibitor
    TAT-JIP inhibits the phosphorylation of endogenous c-jun activated by PHA–PMA.
    TAT-JIP
  • HY-178169
    ETI60
    Inhibitor 99.51%
    ETI60 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 (IC50 = 0.68 μM) and TLR9 (IC50 = 0.12 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5). ETI60 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI60 modulates the expression of genes associated with inflammation. ETI60 effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE). ETI60 can be used for autoimmune and inflammatory diseases research.
    ETI60
  • HY-153149
    LJ-2698
    Inhibitor
    LJ-2698 (FM101) is an orally active adenosine A3 receptor (Adenosine A3 Receptor) antagonist. LJ-2698 blocks adenosine A3 receptor-dependent pro-inflammatory JNK, ERK, and NF-κB signaling pathways. LJ-2698 prevents alveolar cavity enlargement, restores pulmonary function, and inhibits matrix metalloproteinase activity and pulmonary cell apoptosis (apoptosis) in mice. LJ-2698 induces mitochondrial dysfunction, necroptosis, and intrinsic apoptosis. LJ-2698 ameliorates renal injury in mice with diabetic nephropathy, and alleviates diet-induced hepatic inflammation and fibrosis. LJ-2698 can be used in the research of emphysema, diabetic nephropathy, and metabolic dysfunction-associated steatotic liver disease.
    LJ-2698
  • HY-P2243A
    D-JBD19 TFA
    Control
    D-JBD19 TFA is a non-permeable peptide. D-JBD19 TFA has neuroprotective effects.
    D-JBD19 TFA
  • HY-P11298
    d-T101 peptide
    Activator
    d-T101 peptide, a human hormone-peptide, is a T1/ST2 receptor ligand. d-T101 peptide binds to the T1/ST2 receptor and activates caspases 8, 9 and 3 mediated apoptosis, together with activation of JNKinase and p38 MAPKinase. d-T101 peptide also changes Golgi structural with function loss and downregulation of the endoplasmic reticulum (ER) stress repair mechanism. d-T101 peptide has immunostimulatory and anticancer activity, selectively induces apoptosis in proliferating cancer cells and increases IL-2 and IFN-γ expression as well as the recruitment of NK cells and M1 macrophages to the tumor site.
    d-T101 peptide
  • HY-149279
    JNK3 inhibitor-7
    Inhibitor
    JNK3 inhibitor-7 is a potent, orally active and cross the blood-brain barrier JNK3 inhibitor with IC50 values of 53, 973, 1039 nM for JNK3, JNK2, JNK1, respectively. JNK3 inhibitor-7 shows significant neuroprotective effects. JNK3 inhibitor-7 has the potential for the research of Alzheimer’s disease (AD).
    JNK3 inhibitor-7
  • HY-N6032
    Esculentoside B
    Inhibitor 99.88%
    Esculentoside B (Phytolaccoside B) is a natural product from the roots of Phytolacca acinosa Roxb. Esculentoside B is neurotoxic to zebrafish larvae, and impairs their central nervous system development. Esculentoside B inhibits inflammatory response and has antifungal activity.
    Esculentoside B
  • HY-13703
    Nimustine
    Inhibitor
    Nimustine is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity.
    Nimustine
  • HY-181993
    JNK3-IN-11
    Inhibitor
    JNK3-IN-11 is a selective JNK3 inhibitor with an IC50 of 2.08 nM. JNK3-IN-11 binds to the JNK3 ATP-binding pocket, forming conserved hydrogen bonds with Met149 and a water-mediated hydrogen bond with Lys93. JNK3-IN-11 suppresses TGF-β1-induced c-Jun phosphorylation, reduces profibrotic markers COL1A1 and PAI-1, restores E-cadherin expression, and has protection against podocyte injure. JNK3-IN-11 can be used for the research of chronic kidney disease.
    JNK3-IN-11
  • HY-RS08096
    Mapk10 Mouse Pre-designed siRNA Set A
    Inhibitor

    Mapk10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mapk10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mapk10 Mouse Pre-designed siRNA Set A
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.